United Kingdom Monkeypox Therapeutics Market to Grow with a CAGR of 6.54% through 2029

Surge in research and development activities is expected to drive the United Kingdom Monkeypox Therapeutics Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “United Kingdom Monkeypox Therapeutics Market - By Region, Competition, Forecast & Opportunities, 2019-2029F”, the United Kingdom Monkeypox Therapeutics Market stood at USD 18.38 Million in 2023 and is anticipated to grow with a CAGR of 6.54% through 2029. Initiatives taken by government based on monkeypox therapeutics has led to favorable market conditions for the United Kingdom Monkeypox Therapeutics Market. Several factors contribute to the growth of various monkeypox therapeutics products.

The UK government, through the Medicines and Healthcare products Regulatory Agency (MHRA), has expedited the approval process for Monkeypox therapeutics. This includes both antiviral drugs and vaccines, particularly those repurposed from smallpox treatments. The streamlined regulatory pathways are designed to facilitate the rapid availability of effective therapeutics, ensuring that new treatments can be deployed quickly in response to outbreaks.

To advance the development of Monkeypox-specific therapeutics, the UK government has allocated significant funding for research and development (R&D). Agencies such as the Department of Health and Social Care (DHSC) and UK Research and Innovation (UKRI) are supporting research initiatives aimed at discovering new antiviral drugs and optimizing existing treatments. This financial support helps accelerate the R&D pipeline, fostering innovation and enhancing the UK's ability to respond to Monkeypox effectively.

The escalating monkeypox outbreak has underscored the urgent need for effective treatments, spurring a wave of innovation in therapeutic research. In the UK, leading pharmaceutical companies, research institutions, and biotech firms are intensifying their efforts to develop new antivirals, vaccines, and monoclonal antibodies targeted at monkeypox. The surge in R&D activities is driving the rapid advancement of these therapeutics, bringing novel solutions closer to market availability.

Advanced research methodologies, such as high-throughput screening, genomic sequencing, and computational drug design, are playing a critical role in accelerating therapeutic development. These technologies enable researchers to identify promising drug candidates more efficiently, leading to faster progression from preclinical studies to clinical trials. The UK’s emphasis on leveraging cutting-edge technology in R&D is a key factor in the growth of the monkeypox therapeutics market. 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United Kingdom Monkeypox Therapeutics Market”

The United Kingdom Monkeypox Therapeutics Market is segmented into treatment, end user, regional distribution, and company.

Based on Treatment, Antivirals have emerged as the dominated segment in the United Kingdom Monkeypox Therapeutics Market in 2023. Antivirals have demonstrated significant efficacy in treating viral infections, including those caused by orthopoxviruses, the family to which Monkeypox belongs. In particular, drugs like Tecovirimat (TPOXX) and Cidofovir, which were initially developed for smallpox, have shown effectiveness against Monkeypox due to their ability to inhibit viral replication. Tecovirimat, for instance, targets the viral envelope protein essential for the virus’s spread, thereby reducing the severity and duration of the infection. The proven track record of these antivirals in controlling similar viral outbreaks solidifies their dominant position in the Monkeypox Therapeutics Market.

The specificity of antivirals to orthopoxviruses makes them particularly advantageous for treating Monkeypox. Unlike broad-spectrum treatments, antivirals like Tecovirimat and Cidofovir are designed to specifically target the mechanisms of viral replication unique to orthopoxviruses. This targeted approach enhances their effectiveness in managing Monkeypox infections and minimizes the risk of resistance development. The tailored action of these antivirals ensures a more precise and effective treatment regimen for Monkeypox patients.

Based on Region, Scotland have emerged as the fastest growing region in the United Kingdom Monkeypox Therapeutics Market in 2023. Scotland has been at the forefront of implementing proactive public health measures to address monkeypox. The Scottish government has introduced targeted strategies for disease surveillance, rapid response, and containment. These measures have included enhanced diagnostic capabilities, early detection programs, and robust contact tracing, all of which have contributed to an increased demand for effective therapeutics.

There has been a notable increase in funding and investment in Scotland's healthcare sector, specifically aimed at tackling infectious diseases like monkeypox. This financial support has facilitated the development, procurement, and distribution of monkeypox therapeutics. The availability of funds has also supported research and clinical trials, leading to advancements in treatment options and driving market growth.

Major companies operating in United Kingdom Monkeypox Therapeutics Market are:

• Chimerix UK Limited
• SIGA Technologies, Inc.
• Emergent BioSolutions UK Ltd.
• Bavarian Nordic A/S
• Mylan N.V.
• Olon S.p.A.
• Teva UK Limited

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The application of nanotechnology in drug delivery systems offers promising solutions for treating Monkeypox. Nanocarriers, including liposomes, dendrimers, and polymeric nanoparticles, are engineered to deliver antiviral drugs specifically to infected cells while minimizing off-target effects. This targeted approach can enhance the therapeutic efficacy of existing drugs and reduce potential side effects. By optimizing drug delivery, nanotechnology could play a crucial role in improving the overall effectiveness of Monkeypox treatments”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“United Kingdom Monkeypox Therapeutics Market By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG)), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Competition, Forecast & Opportunities, 2019-2029F”, has evaluated the future growth potential of United Kingdom Monkeypox Therapeutics Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United Kingdom Monkeypox Therapeutics Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com